Golden, Colorado—February 18, 2015 Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced advances in its stem cell products and services that enhance opportunities to expand clinical studies of stem therapy of neurological conditions.  We have previously announced a pre-clinical study of our human MSCs for treatment of stroke in animals that showed near reversal of cell death responses to ischemic stroke by carotid artery occlusion.  Recently, the renowned hockey legend, Gordy Howe received a stem cell transplant to treat a prior stroke that left him partially paralyzed, unable to speak and losing weight and quality of life quickly.  Shortly following stem cell transplantation in two stages, neural stem cells (NSCs) followed by mesenchymal stem cells (MSCs) he began to walk and talk.  At present, he is preparing to attend a hockey gala as a keynote speaker. While his progress is considered outstanding by his family and attending physicians, others criticize this study as uncontrolled.  We have recently published a blog summarizing clinical and pre-clinical studies that support further, more extensive clinical trials of stem cell therapy of stroke.

Stem cell therapy is also supported as an effective treatment for traumatic brain injury (TBI) including concussion. Trauma to the brain causes injury to the brain that is similar to the results of stoke, e.g., disruption of blood flow leads to death of brain cells underlying specific functions leading to symptoms such as memory or speech deficits.  The regenerative effects of stem cells include protection of damaged nerve cells, reduction of inflammation & oxidative stress together with growth of new nerve cells, glial cells (that protect and support nerve cells) and blood vessel cells that become new arteries and veins.   These distinct biological actions of stem cells result in overall regeneration of brain damage caused by concussion or TBI.  Stem cells reside within the brain in specific regions and these cells may be activated by certain chemicals and possibly low-level laser light, etc.  Once activated, brain stem cells move to sites of injury and inflammation in the brain, through a complicated system of chemical signals where they regenerate damaged cells.

Vitro Biopharma has developed novel means of brain stem cell activation and procedures to quantify the regenerative responses.  We gained proprietary technology to support development of stem cell activation methods for achieving stem cell therapy during 2014.  We focused on activation of adult stem cells known as mesenchymal (MSC) and neural stem cells (NSC) that require unique signaling pathways as compared to hematopoietic stem cells.  These developments by Vitro Biopharma included analysis of the activation process of MSCs and NSCs, and on enhanced understanding of the activation mechanisms necessary to activate these specific stem cells.  Analysis of stem cell activation is based on biomarker profiling together with unique imaging platforms enabling clinical determination of stem cell activation.  We plan to utilize these methods in upcoming clinical trials to precisely determine the biological effects of stem cell activation.

Dr. Jim Musick, Vitro Biopharma’s President & CEO, said, “Both stroke and concussion are common conditions with limited treatment options.  The drug, TPA is used in some patients with stroke and secondary injury can be minimized in TBI while the mainstay of current treatment remains physical therapy and rehabilitation that can take years to yield results.   The results of proof-of-concept clinical studies support further exploration of the effects of stem cell therapy both by use of appropriate stem cell transplants and activation of stem cells in the brain.  Also, it is likely that both approaches could be of benefit using stem cell activation agents to increase therapeutic efficacy of transplanted stem cells for example.  Vitro Biopharma has proprietary technology and services related to TBI treatment by stem cell activation, including activation agents and numerous diagnostic tests of the effects of stem cell activation.  Also, we offer different stem cell sources for use in transplantation, together with  GMP operating standards that are continually evolving and improving.  Our MSC-Gro™ media is now available as clinical grade and possesses numerous advantages to other commercially available media. We are committed to the translation of stem cell technology and products to clinical applications.  Our team of experts operates at the highest quality standards and possesses considerable expertise in analytical techniques necessary to conduct detailed clinical trials generating meaningful data to assess safety and efficacy.” 

About Vitro Biopharma

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG;, owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes.  In 2011, Vitro Biopharma out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies.  Vitro Biopharma also owns a pending patent for methods and materials related to treatment of neurological conditions by activation of neural stem cells.  Vitro Biopharma’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado.  Vitro Biopharma manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation.  In addition to our FSH patent licensee, Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. (  Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems.  Also, Vitro Biopharma’s CEO is a consultant on an NSF grant at the City College of New York to advise Dr. Lane Gilcrest, Professor of Materials Science and Engineering, and his colleagues regarding the development of novel extracellular materials for use in self-renewal and differentiation of mesenchymal stem cells.

Vitro Biopharma received the Frost and Sullivan Technology Innovation Leadership Award for the industry sector: Stem Cell Tools and Technology in North America, 2014.

Safe Harbor Statement 

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.  Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission.  Most of these factors are outside the control of the Company.  Investors are cautioned not to put undue reliance on forward-looking statements.  Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.


Dr. James Musick
Chief Executive Officer
Vitro Biopharma
(303) 999-2130 Ext. 3

Source: Vitro Diagnostics, Inc.